Clinical Trial

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Study acronym: MRD
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-12-30 -> 2027-06-30 2026-05-05
notable Primary completion pushed: 2026-08-30 -> 2026-12-30 2026-04-14
minor Completion pushed: 2028-01-30 -> 2028-08-30 2026-04-14
Trial Details
NCT Number NCT05739981
Lead Sponsor Imunon
Collaborators: Breakthrough Cancer Research
Conditions Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Enrollment 30 participants
Start Date 2023-02-10
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-04